Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleThe effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Author(s)Boggs DL et al.
Journal, Volume, IssuePsychopharmacology (Berl).
Major outcome(s)CBD did not improve cognition in patients with schizophrenia
IndicationPsychosis/schizophreniaAbstract
MedicationCannabidiol

RATIONALE:
Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS).

OBJECTIVE:
This study compared the cognitive, symptomatic, and side effects of CBD versus placebo in a clinical trial.

METHODS:
This study was a 6-week, randomized, placebo-controlled, parallel group, fixed-dose study of oral CBD (600 mg/day) or placebo augmentation in 36 stable antipsychotic-treated patients diagnosed with chronic schizophrenia. All subjects completed the MATRICS Consensus Cognitive Battery (MCCB) at baseline and at end of 6 weeks of treatment. Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and biweekly.

RESULTS:
There was no main effect of time or drug on MCCB Composite score, but a significant drug × time effect was observed (p&#8201;=&#8201;0.02). Post hoc analyses revealed that only placebo-treated subjects improved over time (p&#8201;=&#8201;0.03). There was a significant decrease in PANSS Total scores over time (p&#8201;<&#8201;0. 0001) but there was no significant drug × time interaction (p&#8201;=&#8201;0.18). Side effects were similar between CBD and placebo, with the one exception being sedation, which was more prevalent in the CBD group.

CONCLUSIONS:
At the dose studied, CBD augmentation was not associated with an improvement in MCCB or PANSS scores in stable antipsychotic-treated outpatients with schizophrenia. Overall, CBD was well tolerated with no worsening of mood, suicidality, or movement side effects.

Route(s)
Dose(s)
Duration (days)
Participants
DesignControlled study
Type of publicationMedical journal
Address of author(s)
Full text

[Back to Overview]  [IACM Homepage]


up